Hi i’m dating builder well i wanted to talk about first is the clinical trial ocular science 1.0 this is a multicenter randomized observer mass prospective study where we compared preservative-free versus the current multiple drug therapy big amok spread for tate and a lever oh primary eligibility of this was patients undergoing unilateral uncomplicated cataract
Surgery total of 80 patients are followed and what we wanted to do was compare to see the safety and efficacy of pred phosphate moxifloxacin and ketorolac four times a day for two weeks then two times a day for two weeks versus bigham ox and pred for tate four times a day for two weeks then two times a day for two weeks with the level once a day for four weeks we
Set out at first to see if the would show non-inferiority to conventional medication we were surprised to see with 90% confidence interval that actually a day 7 cleared the inflammation by 50% compared to only 27 percent with conventional therapy and at day 14 it was 88 percent versus 81 percent at about a month out both were pretty equivalent this was another
Way to look at the data is to look at this bar graphed and looking at the confidence interval you can see that perform better at day 7 day 14 and day 30 compared to conventional medicine so this was important because this is the first time we’re seeing a compound combination medicine not only can be safe but was as effective if not a little bit sooner reduction
In inflammatory clearing than conventional medication another thing i wanted to introduce was the new line of glaucoma medicines ocular science is launching first these are the post-op medications there are three new post-op medications and then a new intro camel medication popular science is a company that is a compounding pharmacy and if you have a patient
That may not call this sort of confusion maybe a little bit of a lower health literacy they can’t remember which drop is when and you know they come in and they say i’m taking these three drops and they’ve got three bottles of latina frost you know they’re taking it in drop you know i’ve seen it all i’ve seen people mix up pred forte and timolol because they get
The cap on the wrong bottle this is you can take your drops you can take lantana procced timolol doors olamide vermont evene put them in one bottle compounded because there’s a lot of high co-pays even with generics these days the compounding price is probably going to be less than their generic copay it’s a bizarre thing but that’s the reality there’s price gap
There has to be price gouging and so you can simplify life for patients and you know we all love fixed combinations the reason we don’t have four in a bottle is because the fda requires a really carefully done study to do that and have it fda approved but we know all these molecules coexist in bottles because they’re all out there in one combination or another
And so this is a way of simplifying things for patients putting it all in one and letting them just have a reasonable quality of life with one bottle in their hand lastly the area i think ocular science is most excited about and i’m excited to present is a new dry eye therapy amniotic cytokine extract we know that when dry eye is a chronic progressive disease
And there gets to be a issue with the way the immune system works on the surface of the eye current medications that are available usually only work on one pathway of reducing inflammation ace will have the ability to work on multiple pathways because it’s loaded with multiple growth factors and multiple cytokines that promote good healing ace is a cryopreserved
Drop stored in the common freezer and will be dosed twice a day ace has reduced dry eye symptoms as soon as two to four weeks and i’m excited to tell you we’ll have more data as a u.s. multicenter trial that’s currently underway will be completed we’ll be presented at oscars 2017 oh oh
Transcribed from video
Ocular Science Clinical Trials 1.0 By Anthony S.
